Citrate Concentrate

Bicarbonate Hemodialysis Citrate Concentrate

Renacit Dry : Citrate Concentrate

RENACIT Dry: Citrate Concentrate


Part-A: Powder Form


Part-B: Powder Form

RENACIT Citrate Concentrate


Part-A: Solution


Part-B: Powder

Product Description

RENACIT is Bicarbonate Hemodialysis Concentrate which contains Sodium Citrate as buffering agent replacing significant amount of Acetate, normally present as buffer. The quantity of Sodium Citrate is very low as compared to that needed for systemic anti-coagulation hence its anti–coagulatory effect is only in extra-corporeal circulation.

RENACIT Part-A is available in solution form & Part-B in powder form. RENACIT DRY is available in powder form (Part-A & Part-B).


Compared with traditional Hemodialysis Concentrates, “RENACIT Citrate Concentrate” has the following benefits:

Reduces Heparin need in dialysis patients (upto 40%)
Increases dialysis dose Kt/V (>1.2) and URR (>70%)
Significantly reduces clotting in case of Heparin-free Hemodialysis
Better Kt/V in case of Dialyzer Reuse due to better clearing of fibres
No of Dialyzer Re-use increases significantly (60-100%)
Does not cause Thrombocytopenia
No Heparin Antibodies
Reduces cost of Heparin
Significant reduction in bleeding episodes if Heparin is eliminated or reduced
No Heparin-related complications viz Osteoporosis, Pruritis, disturbed Lipid Metabolism
Significantly less or no clotting in patients with frequent dialyzer clotting
Elimination of Acetate-related complications (present as buffer in Concentrates)
Anti-oxidative effects
Improved acid-base status
Reduced inflammation
Reduction of Pre-dialytic Beta-2-Microglobulin levels
Improved tolerance to treatment
Heparin-induced Myeloperoxidase release causes atherosclerosis propagation not present with Citrate concentrate
Can be used in Liver Failure patients undergoing Hemodialysis


Routine Hemodialysis due to its advantages
Active Bleeding employing Heparin-free hemodialysis
Suspected bleeding or risk of bleeding
Disturbed clotting profile
Absolute or relative contra-indication of Heparin
Frequent Dialyzer clotting
Heparin Allergies
Low Platelet count
Targeting of better Kt/V with Dialyzer Re-use & increase in number of reuses
Pre-and Post-surgical patients
Patients with gastro-intestinal bleeding or active ulcers
Patients with Hemorrhagic Retinopathies
Patients with Acetate-related complications like frequent episodes of hypotension, arrhythmias, nausea, etc.
Old, malnourished patients or those getting Hemodialysis for several years more prone to Acetate toxicity
Patients with Heparin-related side-effects viz pruritis, osteoporosis, accelerated atherosclerosis, etc.
Hemodialysis in Liver failure patients with disturbed bleeding/clotting profile

Material Safety Data Sheet

Clinical trails on the use of citrate containg dialysates

Heparin Adverse Effects
  • Increased Bleeding Tendency
  • Heparin Anti-bodies
  • Thrombocytopenia
  • Clotting Problems in Dialyzers
  • Osteoporosis
  • Pruritus
U.S. FOOD AND DRUG ADMINISTRATION 2006 Safety Alert: Heparin

Heparin Sodium Injection [Posted 12/08/2006] FDA notified healthcare professionals of revisions to the WARNINGS section of the prescribing information for Heparin to inform clinicians of the possibility of delayed onset of heparin-induced thrombocytopenia (HIT), a serious antibody-mediated reaction resulting from irreversible aggregation of platelets. HIT may progress to the development of venous and arterial thromboses, a condition referred to as heparin-induced thrombocytopenia and thrombosis (HITT). Thrombotic events may be the initial presentation for HITT which can occur up to several weeks after the discontinuation of heparin therapy. Patients presenting with thrombocytopenia or thrombosis after discontinuation of heparin should be evaluated for HIT and HITT

Disadvantages of Acetate in Bicarbonate Concentrates
  • Acetate Contents in Bicarbonate Concentrates :2-10 mmol/l
  • Acetate Oxidation: CO2+H20 .Oxygen consumption leads to Hypoxemia
  • Acetate Reduction: Aldehyde Production:Causes Headache,nausea
  • Vasodilation/Hypotension/Arrhythmias
  • Atherosclerosis
  • Micro-inflammation
  • Old, malnourished patients and those getting Hemodialysis for several years are more prone to Acetate Toxicity

RENACIT has very little Acetate contents: 0.3 mmol/litre

Guidelines for Use

RENACIT contains a small amount of anticoagulant (Citrate) which prevents clotting in the extra-corporeal circuit without increasing bleeding tendency.

  • Citrate dialysate can only be prescribed by, or on order of a physician.
  • Before use check label, proportioning ratio (35-X; 36.8-X; 45X) and formulation
  • Use cartridge or B-Part concentrate as usual.
  • To achieve adequate anti-coagulation Dialysate flow may be increased to 600ml/minute.
  • Micro-bubbles cause increased clotting of fibres/circuit hence make sure no air (micro bubbles) are in the extracorporeal circuit before connecting the patient and during dialysis.
  • Reduce the Heparin dose in steps until required ACT or aPTT levels are achieved.
  • In case of Heparin-induced Thrombocytopenia or Heparin allergy stop Heparin and use saline flushing along with use of RENACIT Concentrate to avoid clotting and achieve adequate clearances.
  • Pay special attention to the Venous pressure and clotting in lines if Heparin eliminated or significantly reduced.
  • If there is tendency of frequent clotting of dialyzer/lines, RENACIT can be used with the normal Heparin dose.
  • If RENACIT Part-A solution is still available after Dialysis it can be used for the next Dialysis session.
  • Electrolytes like Calcium, Potassium can be added in Part-A as per Physician’s choice.

Rarely in case of very low Calcium in patient’s blood signs of Hypocalcemia may appear. Calcium binds with Citrate and hence use of Citrate dialysate will temporarily, during dialysis only, decrease ionized Ca levels by approximately 10%. Assess the patient during treatment for signs of hypocalcemia: numbness/tingling around the mouth, spasm of hand muscles (Tetany), unusually long and strong muscle cramps(not related to Hypo-natremia). If symptoms occur, place the hemodialysis machine in bypass and give I/V Calcium Gluconate slowly although even otherwise symptoms should resolve in minutes as Citrate is quickly metabolised in the body.

Frequently Asked Questions
Q: Is frequent or continuous intra-venous Calcium is necessary during Hemodialysis with RENACIT?

Answer: No. Calcium binding by dialysate Citrate is very small and only 10% of the Ionized Calcium may decrease in the blood. There is also the usual amount of calcium in the dialysate.

Q: How does Citrate dialysate function?

Answer: Citrate, being an anti-coagulant, is present in very little amount in the Dialysate. Hence anti-coagulation effect is only in the extra-corporeal circuit and it is rapidly neutralized upon entry in the systemic circulation.

Q: Is it necessary to check clotting times when RENACIT is used?

Answer: No.

Q: Is there reason to be concerned about bleeding risk?

Answer: No. Citrate is a local anticoagulant, it means that it does not have systemic anticoagulation effects. Once blood is returned to the patient the citrate is uncomplexed from calcium and is readily metabolized.

Q: Is there reason to be concerned about hypocalcemia, or hypomagnesemia when treating patients with citrate dialysate?

Answer: The concentration of Citrate in the dialysate is low, so is the risk of hypocalcemia or hypomagnesemia with normal concentrations of dialysate calcium and magnesium.

Q: When using RENACIT what changes I should make in the present Dialysis System?

Answer: No changes are required.The existing Dialysis system is fully compatible to use RENACIT.

Q: What are the advantages regarding Dialyzer Reuse?

Answer: Dialyzers’ fibers are properly cleared with use of RENACIT hence number of dialyzer reuse increases while clearances (Kt/V) increase or remains fairly good.

Q: Is RENACIT much more expensive than other Bicarbonate Concentrates?

Answer: No. Inspite of significant advantages there is no significant difference in price.